Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Muller

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Stroke|November 23, 2022
Ultra-Long Transfers for Endovascular Thrombectomy-Mission Impossible?: The Australia-New Zealand ExperienceCarlos Garcia-Esperon, Teddy Y Wu, Vinicius Carraro do Nascimento, et al.
Journal of Medicinal Chemistry|November 14, 2019
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast CancerYoussef El-Ahmad, Michel Tabart, Frank Halley, et al.
The New England Journal of Medicine|April 26, 2018
Tenecteplase versus Alteplase before Thrombectomy for Ischemic StrokeBruce C V Campbell, Peter J Mitchell, Leonid Churilov, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Stroke|November 23, 2022
Ultra-Long Transfers for Endovascular Thrombectomy-Mission Impossible?: The Australia-New Zealand ExperienceCarlos Garcia-Esperon, Teddy Y Wu, Vinicius Carraro do Nascimento, et al.
Journal of Medicinal Chemistry|November 14, 2019
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast CancerYoussef El-Ahmad, Michel Tabart, Frank Halley, et al.
The New England Journal of Medicine|April 26, 2018
Tenecteplase versus Alteplase before Thrombectomy for Ischemic StrokeBruce C V Campbell, Peter J Mitchell, Leonid Churilov, et al.
Pageof 3